We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
-24.17%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$62M
AUM Growth
-$91.4M
Cap. Flow
-$70.4M
Cap. Flow %
-113.48%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$70.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$50.6M 81.68%
10,230,349
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$11.4M 18.32%
2,790,964
BPMC
3
DELISTED
Blueprint Medicines
BPMC
-878,875
Closed -$70.4M

Similar funds

TRV GP II's Q2 2019 Portfolio in Review

As of Q2 2019, TRV GP II held 3 positions worth $62M, down 60% from $153M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $70.4M in Q2 2019, closing 1 position. Its most notable exit was Blueprint Medicines, an estimated $70.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II fully exited Blueprint Medicines in Q2 2019, selling an estimated $70.4M.
  • TRV GP II's ten largest holdings make up 100% of its $62M portfolio in Q2 2019.
  • TRV GP II opened 0 new positions and closed 1 in Q2 2019.
  • TRV GP II's portfolio value fell 60% quarter-over-quarter to $62M.

Based on TRV GP II's 13F filing for Q2 2019, filed 6 Aug 2019.